Lower-Risk MDS: A Review of Data from the ASH 2022 Annual Meeting : Episode 1

First- and Second-Line Treatment Options in Lower-Risk MDS

February 24, 2023

Rami Komrokji, MD
Amer Zeidan, MBBS, MHS

Video

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

EP: 1.First- and Second-Line Treatment Options in Lower-Risk MDS

EP: 2.Luspatercept in Lower-Risk MDS

EP: 3.Emerging Therapies for Lower-Risk MDS

Related Videos

Timothy Yap, MBBS, PhD, FRCP

Carrie L. Kitko, MD

Lori A. Leslie, MD

Amin Nassar, MD

Debu Tripathy, MD

Lori A. Leslie, MD

Debu Tripathy, MD

Changchun Deng, MD, PhD

Parul N Barry, MD,

Ramez Kouzy, MD, MD Anderson

Related Content

Katie S. Gatwood, PharmD, BCOP, a clinical pharmacist specialist in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center

Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Carrie L. Kitko, MD

CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL

Amin Nassar, MD, hematology/oncology fellow, Yale University; Elias Bou Farhat, MD, postdoctoral research fellow, Department of Medicine, Brigham and Women’s Hospital

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

April 29th 2024

WU-CART-007 for R/R T-ALL and T-LBL| Image Credit: © Dr_Microbe - stock.adobe.com

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD

Related Content

Katie S. Gatwood, PharmD, BCOP, a clinical pharmacist specialist in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center

Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Carrie L. Kitko, MD

CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL

Amin Nassar, MD, hematology/oncology fellow, Yale University; Elias Bou Farhat, MD, postdoctoral research fellow, Department of Medicine, Brigham and Women’s Hospital

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

April 29th 2024

WU-CART-007 for R/R T-ALL and T-LBL| Image Credit: © Dr_Microbe - stock.adobe.com

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD

Latest Conference Coverage

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age

AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.